United States public health guidelines from the Advisory Committee on Immunization Practices (ACIP) on the quadrivalent HPV vaccine licensed in 2006. The report summarizes HPV epidemiology, describes the vaccine, and provides recommendations for vaccination among females aged 9-26 years. It was authored by Lauri E. Markowitz of the National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention.
Use Cases
- Analyzing the rationale for HPV vaccination recommendations based on the described epidemiology of 6.2 million annual new infections.
- Studying the clinical trial efficacy of the quadrivalent vaccine against persistent infection and precursor lesions for types 6, 11, 16, and 18.
- Modeling the public health impact of catch-up vaccination strategies for females aged 13-26 based on the provided schedule and age recommendations.
Strengths
- Provides specific epidemiological figures, including an estimated 6.2 million new HPV infections annually in the U.S. and 11,100 new cervical cancer cases in 2007.
- Details concrete vaccine recommendations, including the 3-dose schedule and target age groups of 11-12 years with catch-up to age 26.
- Describes the vaccine composition and mechanism, specifying it contains VLPs for HPV types 6, 11, 16, and 18.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Last update date is unknown; freshness unverified.
- Row count is unknown, which may limit suitability assessment.
Provenance
- Source
- Advisory Committee on Immunization Practices (ACIP), U.S. Centers for Disease Control and Prevention
- Collection Method
- Clinical guidelines and recommendations report.
- Time Range
- Recommendations pertain to the vaccine licensed in June 2006 and reference data from 2007.
- Geography
- United States